Souhaitez-vous accéder aux communiqués récents ?

HUDDINGE, Sweden, Feb. 24, 2004 (PRIMEZONE) -- The Annual General Meeting of Tripep AB will be held on 25 March 2004 at 6 p.m. at the Kilsalen Room, Berns Conference Facility, Berzelii Park,...

HUDDINGE, Sweden, Feb. 04, 2004 (PRIMEZONE) -- Dormant Properties AB, a company controlled by Tripep's Chairman of the Board, Rolf L. Nordstrom, acquired a total of 86,000 Tripep AB shares on 3...

HUDDINGE, Sweden, Jan. 30, 2004 (PRIMEZONE) -- Tripep AB (publ): - Loss after tax for the full year 2003: SEK -13.0 million (SEK - 42.5 m). Research and development costs for the full year 2003:...

HUDDINGE, Sweden, Jan. 21, 2004 (PRIMEZONE) -- Tripep has secured a new patent, granted in the U.S. today. The patent states the discovery that ribavirin can be used to reinforce the immune defence...

HUDDINGE, Sweden, Dec. 19, 2003 (PRIMEZONE) -- Tripep has received remission of half the loan of SEK 20 million from Industrifonden. As announced earlier, Tripep had applied for remission of the SEK...

HUDDINGE, Sweden, Nov. 10, 2003 (PRIMEZONE) -- Dormant Properties AB, a company controlled by Tripep's Chairman of the Board, Rolf L. Nordstrom, acquired a total of 269,000 Tripep AB shares on 4 and...

HUDDINGE, Sweden, Oct. 30, 2003 (PRIMEZONE) -- Tripep has identified the active component of GPG Clarification concerning alfaHGA, Tripep's new candidate drug against HIV. Yesterday, the O-listed...

HUDDINGE, Sweden, Oct. 29, 2003 (PRIMEZONE) -- This letter concerns the dissemination of the press release alpha HGA, new candidate drug against HIV from TRIPEP earlier this morning at 07:30...

HUDDINGE, Sweden, Oct. 27, 2003 (PRIMEZONE) -- Tripep AB (publ) - Interim Report, January - September 2003 . Result after tax: -SEK 17.2 million (-SEK 38.9 m). Research and development...

HUDDINGE, Sweden, Sept. 01, 2003 (PRIMEZONE) -- Tripep AB (publ): - Result after tax: -SEK 11.9 million (-SEK 32.5 m). Research and development costs: SEK 6.6 million (SEK 9.4 m). The company has...